Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06716021

ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 (ReVeRA-301)

Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atrial Fibrillation and Rapid Ventricular Rate (RVR)

Sponsor: Milestone Pharmaceuticals Inc.

Conditions Atrial Fibrillation

Interventions Etripamil Placebo

Updated 3 times since 2025 Last updated: Jan 13, 2026 Started: Jan 31, 2027 Primary completion: Jan 31, 2029 Completion: Jan 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06716021, this PHASE3 trial focuses on Atrial Fibrillation and remains actively recruiting participants. Sponsored by Milestone Pharmaceuticals Inc., it has been updated 3 times since 2027, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

3 versions recorded

Feb 2026 — Present [monthly]

Not Yet Recruiting PHASE3
Jul 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE3
Jan 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Milestone Pharmaceuticals Inc.

Data source: Milestone Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.